Hexyl aminolevulinate - Photocure

Drug Profile

Hexyl aminolevulinate - Photocure

Alternative Names: 5-ALA hexylester; 5-ALA hexylesther; aminolevulinic acid hexyl ester; Cevira; Cysview; HAL-PDT; hexaminolevulinate; Hexvix; Hexvix PDT; hexyl 5-aminolevulinate; P 1206

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PhotoCure
  • Developer Ipsen; Juno Pharmaceuticals; Photocure
  • Class Amino acids; Antineoplastics; Esters; Levulinic acids; Oxidants; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cervical intraepithelial neoplasia

Highest Development Phases

  • Marketed Bladder cancer
  • Phase II Cervical intraepithelial neoplasia
  • Discontinued Colorectal cancer

Most Recent Events

  • 18 Oct 2017 Photocure anticipates the approval of sNDA in the US for use of BLC™ with Cysview® using KARL STORZ D-Light C PDD Flexible Videoscope System for the diagnosis of Bladder cancer in the first half of 2018
  • 18 Oct 2017 US FDA accepts sNDA and grants priority review status for hexyl aminolevulinate for Bladder cancer (Diagnosis)
  • 16 Aug 2017 Photocure submits sNDA to US FDA to seek approval for use of BLC™ with Cysview® using KARL STORZ D-Light C PDD Flexible Videoscope System, for the diagnosis of Bladder cancer, to expand the indication to include detection of carcinoma in situ and to allow for repeated use
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top